Exelixis Inc. (EXEL)

Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.

Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investo...

Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push ...

On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's...

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opd...